Introduction 43
Various potential health promoting and disease risk reducing activities for milk proteins and 44 milk-derived peptides have been reported (FitzGerald & Meisel, 2003; Pihlanto, 2006) . Insulin 45 secretion from pancreatic beta cells in the presence of glucose is influenced by incretins such as 46 glucose dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).
Enzymatic degradation of these hormones by dipeptidyl peptidase IV (DDP-IV) activity can 48 significantly reduce their level in vivo (Guasch, Ojeda, González-Abuín, Sala, Cereto-Massagué, 49
Mulero, et al., 2012). It has been reported that peptides with 2-8 amino acid containing 50 hydrophobic amino acid residues including Pro residues can inhibit DPP-IV. It has also been 51
shown that milk derived peptides can inhibit DPP-IV activity (Lacroix & Li-Chan, 2012a , 2012b 52 Nongonierma & FitzGerald, 2013) . Food protein derived DDP-IV inhibitory peptides may play a 53 role in type 2 diabetes management by increasing the half-life of GIP and GLP-1 Chan, 2012a). 55
Cardiovascular and renal disease are complications associated with type 2 diabetes and insulin 56 resistance syndrome. A link between hyperuricemia, the development of atherosclerosis, 57 hypertension and insulin resistance has been proposed (Hayden & Tyagi, 2001) . In type 2 58 diabetes patients, the enzyme-based antioxidant systems involving superoxide dismutase, 59 glutathione peroxidase and catalase may be depleted arising from increased oxidative stress 60 (Hayden & Tyagi, 2001 ). An increase in the concentration of reactive oxygen species (ROS) in 61 endothelial cells can result in endothelial injury. Supplementation of anti-oxidants through dietary 62 intake has been proposed as a means to counteract oxidative stress. The in vitro anti-oxidative 63 properties of milk proteins and peptides have been reviewed (Pihlanto, 2006; Power, Jakeman, & 64 FitzGerald, 2012 ). An increase in the concentration of ROS can occur during the oxidation of 65 xanthine to uric acid catalyzed by xanthine oxidase (XO). It has recently been shown that Trp-66 containing dipeptides inhibit XO activity (Nongonierma & FitzGerald, 2012) . 67
Quantitative structure activity relationship (QSAR) and molecular docking approaches have 68 been used to predict peptide binding to proteins (Pripp, 2007) . While molecular docking 69 strategies have been widely used as virtual screening tools for development of active substances 70 in the pharmaceutical sector there appears to be limited use of this approach in the study of 71 dietary compounds (Pripp, 2007) . Some studies have used docking strategies to identify new 72 peptide sequences with angiotensin converting enzyme (ACE) inhibitory properties or to better 73 understand the interaction of peptides with ACE (Norris, Casey, FitzGerald, Shields, & Mooney, 74 2012; Pripp, 2007) . The peptide docking strategy developed by Norris et al. (2012) led to the 75 discovery of two new dipeptide sequences (Asp-Trp and Trp-Pro) with potent in vitro ACE 76 inhibitory properties. A good agreement between the Vina score and IC 50 value was found for 77 some dipeptides. 78
No previous docking studies of peptides with XO have been conducted to our knowledge. 79
Molecular docking of various flavonoids with XO has been carried out (Umamaheswari, 80 Madeswaran, Asokkumar, Sivashanmugam, Subhadradevi, & Jagannath, 2012). Various potent 81 DPP-IV inhibitors originating from natural products have recently been identified using a virtual 82 screening procedure. A further increase in the DPP-IV inhibitory properties was achieved using 83 derivatives of the most potent inhibitor (Guasch, et al., 2012) . In a recent study, amaranth derived 84 peptides with ≥ 13 amino acid residues have been docked with DPP-IV. The mechanism of 85 inhibition of these relatively large peptides has been shown to involve blockage of the active 86 DPP-IV dimer formation (Velarde-Salcedo, Barrera-Pacheco, Lara-González, Montero-Morán, 87
Díaz-Gois, González de Mejia, et al., 2013). 88
Given the link between diabetes and elevated ROS, it was decided to study the role if amino 89 acids and dipeptides in controlling the activity of DPP-IV and XO. The aim of this study was 90 therefore to determine the potential of amino acids and dipeptides to act as natural XO and DPP-91 IV inhibitors. Protein-ligand docking (LIGPLOTs) and virtual screening with Autodock Vina 92 were used to assess the XO and DPP-IV inhibitory properties of amino acids and dipeptides. 93 Furthermore, the type of XO and DPP-IV inhibition mediated by the amino acids and dipeptides 94 was determined using Lineweaver and Burk kinetic analysis. 95 
Materials and methods

XO inhibition assay 109
The test samples (amino acids and dipeptides) were dispersed in HPLC grade water at 110 concentrations ranging from 0.001 to 2.0 mg.mL -1 . The XO inhibition assay was carried out as 111 essentially described by Nongonierma & FitzGerald (2012 
DPP-IV inhibition assay 125
The test samples were dispersed in HPLC grade water at concentrations ranging from 0.01 to 126 1.25 mg.mL -1 . The DPP-IV inhibition assay was carried out as described by Lacroix (Table 1 ) and docked to the PDB structure 3BDJ. Six ligand inhibitors of 7 DPP-IV were taken from their respective PDB files (Table 1) 
Statistical analysis 166
For experimental data, means comparison was carried out with a one way ANOVA followed 167 by a Tukey's test using SPSS (version 9, SPSS Inc., Chicago, IL, USA) at a significance level P 168 been previously been reported by Nongonierma & FitzGerald (2012) . 183
DPP-IV inhibitory properties of amino acids and dipeptides 184
DPP-IV inhibition was observed with 3 amino acids (Met, Leu and Trp). The IC 50 values for 185
Met, Leu and Trp were 2381.51 ± 25.44, 3419.25 ± 55.68 and 4280.40 ± 48.03 µM, respectively 186 (Table 2) . With the exception of Phe-Leu and Trp-Val, the Vina score for Val-Trp (-7.0) was 187 lower than that of the other dipeptides with DPP-IV inhibitory properties (Table 2) . However, 188
Val-Trp did not inhibit DPP-IV. Similarly, two other dipeptides with a Vina score ≤ -7.0 (Arg-189
Trp and Lys-Trp) did not inhibit DPP-IV (Table 2) For XO, most of the compounds studied had Vina scores between -6.0 and -5.5 ( Fig. 3a) . By 199 comparison, the Vina scores obtained for quercetin and mercaptopurine, compounds also known 200 to inhibit XO, were -9.5 and -5.7, respectively when docked with 3BJD (Table 1) . With the 201 exception of Trp, Phe and Tyr which had values of -6.8, -7.0 and -7.4, respectively, the Vina 202 scores for the amino acids were greater than -6.5 ( Table 2 ). The Vina scores ranged between -4.6 203 and -7.8 for the 15 dipeptides studied, while all Trp-containing dipeptides had Vina scores ≤ -7.0 204 (Table 2) . Differences in the interaction with XO were evident in the LIGPLOTs for Allopurinol, 205
Trp, Val-Trp and Trp-Val ( Fig. 4a, 4b, 4c and 4d). It was seen that docking between XO and Trp 206 or Trp-containing dipeptides in the study herein involved interactions with at least with 6 207 hydrophobic amino acid residues in XO. On the other hand, only 3 hydrophobic interactions were 208 seen in the docking pose with Allopurinol ( Fig. 4a ). 209
For interaction with DPP-IV, most compounds had a score between -7.5 and -6.5 ( Fig. 3b and  210 3c) while the Vina scores for the ligand inhibitors when docked with 1ORW ranged between -8.3 211 and -5.2 (Table 1) . Amino acids had Vina scores between -6.2 and -3.4. Of the 15 dipeptides 212 studied, seven had Vina scores ≤ -6.5, five of which were Trp-containing dipeptides ( Table 2) . 213
The distribution of Vina scores for the amino acids, dipeptides and ligand inhibitors were similar 214 for porcine and human DPP-IV (data not shown). A linear relationship (slope = 1.03, R 2 = 0.902) 215 was observed between Vina scores for the different compounds studied with 1WCY (human 216 DPP-IV) and 1ORW (porcine DPP-IV) (see supplementary Leu, Ile-Trp, Ala-Leu, Val-Ala and Ser-Leu) unstable (Table 2) . Of the 15 dipeptides tested, the 223 dipeptide with the lowest XO and DPP-IV Vina score and predicted to be intestinally stable was 224 Ser-Phe. With the exception of Trp-Val, which was neutral, all Trp-containing dipeptides were 225 predicted to have a low intestinal stability (Table 2) . XO was -6.8, indicative of a good interaction with the active site of XO (Table 2) . Surprisingly are also inhibitors of DPP-IV (Hatanaka, et al., 2012) . It is interesting to note that Ile-Pro, which 295 is released following the hydrolysis of Diprotin A by DPP-IV, has a lower Vina score (-6.6) than 296 that of Diprotin A (-5.9). This may suggest that Ile-Pro is a more potent inhibitor than Diprotin A. 297
Similarly, it has been suggested that some food-derived peptides may present structural analogies 298 with DPP-IV substrates and behave as substrates for this enzyme (Lacroix & Li-Chan, 2012a). In 299 such cases, the peptides may compete with the synthetic substrate used in the DPP-IV assay (Gly-300 Pro-pNA) for binding to the active site. This would result in a reduction in the release of pNA, 301 leading to a false positive in the DPP-IV assay. However, it is unlikely that amino acids and dipeptides studied herein could act as substrates for DPP-IV as substrates for this enzyme should 303 possess more than 2 amino acid residues (Engel, et al., 2006) . Most of the DPP-IV inhibitors 304 studied herein were competitive inhibitors with the exception of Trp-Val which was non-305 competitive ( Table 2 ). An hydrophobic pocket at the active site of DPP-IV, composed of Tyr-306 666, Tyr-662, Val-711, Val-656, and Trp-659, has previously been described (Engel, et al., 307 2003) . The LIGPLOTs of Diprotin A and Trp, two competitive inhibitors of DPP-IV, show that 308 these inhibitors interact with the hydrophobic pocket of the active site involving Tyr-666 and 309
Tyr-662 residues of DPP-IV ( Fig. 4e and 4f ). For the other competitive inhibitors of DPP-IV 310 (Leu, Phe-Leu, His-Leu, Glu-Lys, Ala-Leu, Val-Ala, Ser-Leu and Gly-Leu), the LIGPLOTS 311 properties of the subsequent hydrolysate were not impaired. This suggests that Trp and Trp-344 containing components from this LF hydrolysate were still bioactive (Nongonierma & 345 FitzGerald, 2012) . It has been shown that LF hydrolysates which contain Trp and Trp-containing 346 dipeptides could inhibit XO. A consequence of Trp-containing dipeptide cleavage by intestinal 347 enzymes may be reduced bioavailability of Trp compared to the dipeptide. It has been shown that 348 dipeptide uptake in vivo is more efficient than that for free amino acids (Adibi & Morse, 1971) . 349
In order to interact with XO, an inhibitor should cross the gut barrier and survive serum peptidase 350 activity in order to reach locations containing XO (i.e. plasma, liver, gut, lung, kidney, brain and 351 heart). However as hydrophobic peptides have been associated with a high intestinal trans-352 epithelial permeation, Trp and Trp-containing dipeptides may be good candidates for XO 353 inhibition as suggested elsewhere (Nongonierma & FitzGerald, 2012) .
In the case of DPP-IV, Trp-Val and Trp were also inhibitors. However, the IC 50 of Trp was 355 more than 60 times higher than that of Trp-Val, suggesting that hydrolysis increase DPP-IV inhibitory activity following the release of Trp. In the case of Leu-containing 367 dipeptides (i.e. Phe-Leu, Ala-Leu, Ser-Leu and Gly-Leu), cleavage of the dipeptides will result in 368 a decrease in the potency of the sample as the IC 50 value for Leu is between 1.3 and 23.9 times 369 greater than that of the dipeptides. Based on the absence of DPP-IV inhibition with Val and Ala, 370 it is predicted that cleavage of Val-Ala, which is intestinally unstable, would result in a loss in 371 DPP-IV inhibitory activity. LPQNIPPL from gouda-type cheese and its effect on plasma glucose in rats. International 480 Crystal structure of xanthine oxidase in complex with lumazine -7.7 3NRZ
Crystal structure of bovine xanthine oxidase in complex with hypoxanthine -6.7 3NS1
Crystal structure of bovine xanthine oxidase in complex with 6-mercaptopurine -5.7 3NVW
Crystal structure of bovine xanthine oxidase in complex with guanine -7.1 3NVY
Crystal structure of bovine xanthine oxidase in complex with quercetin -9.5 3NVZ
Crystal structure of bovine xanthine oxidase in complex with indole-3-aldehyde -7.7
Dipeptidyl peptidase (DPP-IV) 1ORW
Crystal structure of porcine dipeptidyl peptidase IV (CD26) in complex with a peptidomimetic inhibitor -5.9 1WCY
Crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with Diprotin A -6.2 2AJ8
Porcine dipeptidyl peptidase IV (CD26) in complex with 7-benzyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione (BDPX) -7.8
2AJC
Porcine dipeptidyl peptidase IV (CD26) in complex with 4-(2-aminoethyl)-benzene sulphonyl fluoride (AEBSF) -5.2 2BUA
Crystal structure of porcine dipeptidyl peptidase IV (CD26) in complex with a low molecular weight inhibitor -5.6 2BUC
Crystal structure of porcine dipeptidyl peptidase IV (CD26) in complex with a tetrahydroisoquinoline inhibitor -8.3 
